Report
FREE
• Cannara reported Q2/26 revenue of $27.2M (+2% YoY), missing our estimates due to seasonal provincial purchasing trends which should reverse over the coming quarters, resuming higher levels of growth.
• Gross margin of 43% exceeded expectations and remained above management’s targets, highlighting continued operational efficiency.
• Market share continued to expand nationally and in Quebec, reinforcing Cannara’s relative strength despite declining industry sales.
• We recently initiated coverage on Cannara (see here) and published our first management interview with CFO Nicholas Sosiak (view here).
This morning, Cannara Biotech Inc. (LOVE:TSX, LOVFF:OTCQX, FRA:8CB0) reported its Q2/26 earnings that came in below our estimates due to normal post-holiday seasonality in provincial purchasing board patterns. However, gross margins exceeded our expectations, and national market share continued to grow in a quarter where the overall retail cannabis market declined 4%. We remind readers that we recently initiated coverage on Cannara (read here), citing its growth trajectory, best-in-class profitability, and limited dilution. We view the quarter as a minor road bump in the story, with stronger financial results in the quarters to come. We are maintaining our BUY rating and $3.00/share target price on LOVE.
Q2 Financial Highlights
• Q2/26 revenue came in at $27.2M (+2% YoY), below our estimate of $30.3M and consensus of $31.7M (as per Capital IQ), reflecting post-holiday seasonality in provincial board purchasing patterns (particularly in Quebec), together with lower wholesale channel revenues and a normalization of vape sales following the strong launch. Management stated that this is largely a timing issue and higher growth should resume in the coming quarters.
• Estimated national retail market share reached 4.4% in Q2/26, up from 4.1% in Q1/26, with Quebec market share of 14.3% vs. 13.5% in Q1/26. Cannara maintained its #1 position in Quebec and grew its share in most key provinces.
• Gross margin for the quarter was 43%, above our 41% estimate and management’s >40% target, though down QoQ.
• Adjusted EBITDA for Q2 came in at $6.0M (22% margin) vs. our estimate of $6.7M and $7.1M in Q2/25. G&A was 12% of sales compared to 11% in Q2/25 as the Company builds out its organizational structure.
• Net income for the quarter was $1.7M vs. our estimate of $3.1M. EPS was $0.02 vs. our estimate of $0.03. Operating expenses increased 38% YoY to $8.4M, reflecting deliberate investments in sales and marketing and R&D.
• Operating cash flow was $2.9M with free cash flow of ($0.3M) as the Company advanced construction of the Valleyfield Facility. Capex was $3.2M in the quarter vs. our $4.0M estimate.
• Cannara ended the quarter with $21.9M in cash and $34.4M in debt.
LOVE: Soft Quarter; Still Outperforming the Sector
What you need to know:• Cannara reported Q2/26 revenue of $27.2M (+2% YoY), missing our estimates due to seasonal provincial purchasing trends which should reverse over the coming quarters, resuming higher levels of growth.
• Gross margin of 43% exceeded expectations and remained above management’s targets, highlighting continued operational efficiency.
• Market share continued to expand nationally and in Quebec, reinforcing Cannara’s relative strength despite declining industry sales.
• We recently initiated coverage on Cannara (see here) and published our first management interview with CFO Nicholas Sosiak (view here).
This morning, Cannara Biotech Inc. (LOVE:TSX, LOVFF:OTCQX, FRA:8CB0) reported its Q2/26 earnings that came in below our estimates due to normal post-holiday seasonality in provincial purchasing board patterns. However, gross margins exceeded our expectations, and national market share continued to grow in a quarter where the overall retail cannabis market declined 4%. We remind readers that we recently initiated coverage on Cannara (read here), citing its growth trajectory, best-in-class profitability, and limited dilution. We view the quarter as a minor road bump in the story, with stronger financial results in the quarters to come. We are maintaining our BUY rating and $3.00/share target price on LOVE.
Q2 Financial Highlights
• Q2/26 revenue came in at $27.2M (+2% YoY), below our estimate of $30.3M and consensus of $31.7M (as per Capital IQ), reflecting post-holiday seasonality in provincial board purchasing patterns (particularly in Quebec), together with lower wholesale channel revenues and a normalization of vape sales following the strong launch. Management stated that this is largely a timing issue and higher growth should resume in the coming quarters.
• Estimated national retail market share reached 4.4% in Q2/26, up from 4.1% in Q1/26, with Quebec market share of 14.3% vs. 13.5% in Q1/26. Cannara maintained its #1 position in Quebec and grew its share in most key provinces.
• Gross margin for the quarter was 43%, above our 41% estimate and management’s >40% target, though down QoQ.
• Adjusted EBITDA for Q2 came in at $6.0M (22% margin) vs. our estimate of $6.7M and $7.1M in Q2/25. G&A was 12% of sales compared to 11% in Q2/25 as the Company builds out its organizational structure.
• Net income for the quarter was $1.7M vs. our estimate of $3.1M. EPS was $0.02 vs. our estimate of $0.03. Operating expenses increased 38% YoY to $8.4M, reflecting deliberate investments in sales and marketing and R&D.
• Operating cash flow was $2.9M with free cash flow of ($0.3M) as the Company advanced construction of the Valleyfield Facility. Capex was $3.2M in the quarter vs. our $4.0M estimate.
• Cannara ended the quarter with $21.9M in cash and $34.4M in debt.
Underlying
CANNARA BIOTECH INC.
Provider
Atrium Research Corporation
Atrium Research provides institutional quality issuer paid research on North American public equities using deep fundamental analysis. Our research reports are disseminated through Bloomberg, FactSet, Capital IQ, Reuters and many more, as well as through our social media and email distribution lists.
Nicholas Cortellucci, CFA
Other Reports on these Companies
Other Reports from Atrium Research Corporation
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.